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Abstract
Background: In February 2008, the results of the PRObiotics in PAncreatitis TRIAl (PROPATRIA) were published. This study
investigated the use of probiotics in patients suffering from severe acute pancreatitis. No differences between the groups
were found for any of the primary endpoints. However, mortality in the probiotics group was significantly higher than in the
placebo group. This result was unexpected in light of the results of the animal studies referred to in the trial protocol. We
used the methods of systematic review and meta-analysis to take a closer look at the relation between the animal studies
on probiotics and pancreatitis and the PROPATRIA-trial, focussing on indications for harmful effects and efficacy.
Methods and results: Both PubMed and Embase were searched for original articles concerning the effects of probiotics in
experimental acute pancreatitis, yielding thirteen studies that met the inclusion criteria. Data on mortality, bacterial
translocation and histological damage to the pancreas were extracted, as well as study quality indicators. Meta-analysis of
the four animal studies published before PROPATRIA showed that probiotic supplementation did not diminish mortality,
reduced the overall histopathological score of the pancreas and reduced bacterial translocation to pancreas and mesenteric
lymph nodes. Comparable results were found when all relevant studies published so far were taken into account.
Conclusions: A more thorough analysis of all relevant animal studies carried out before (and after) the publication of the
study protocol of the PROPATRIA trial could not have predicted the harmful effects of probiotics found in the PROPATRIA-
trial. Moreover, meta-analysis of the preclinical animal studies did show evidence for efficacy. It may be suggested, however,
that the most appropriate animal experiments in relation to the design of the human trial have not yet been conducted,
which compromises a fair comparison between the results of the animal studies and the PROPATRIA trial.
Citation: Hooijmans CR, de Vries RBM, Rovers MM, Gooszen HG, Ritskes-Hoitinga M (2012) The Effects of Probiotic Supplementation on Experimental Acute
Pancreatitis: A Systematic Review and Meta-Analysis. PLoS ONE 7(11): e48811. doi:10.1371/journal.pone.0048811
Editor: Juan Sastre, University of Valencia, Spain
Received June 14, 2012; Accepted October 5, 2012; Published November 13, 2012
Copyright:  2012 Hooijmans et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The ZonMW program ’Dierproeven begrensd’ in the Netherlands (ZonMW is a scientific organization for health research and development); Grant
No. 114000089 and 114000103 funded this project. ZonMW had no role in study design, data collection and analysis, decision to publish, or preparation of the
manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: C.Hooijmans@cdl.umcn.nl
Introduction
In February 2008, Besselink et al. published the results of a
randomized clinical trial (RCT) on the use of probiotics in patients
suffering from severe acute pancreatitis: the PRObiotics in
PAncreatitis TRIAl (PROPATRIA) [1]. A total of 296 patients
were enrolled in this study, with 152 in the experimental probiotic
group and 144 in the placebo group. The study product, a food
supplement called Ecologic 641 (1010 bacteria) or placebo was
administered twice daily and added to the continuously running
fibre-enriched tube feeding for a maximum of 28 days. No
differences between the groups were found for any of the primary
endpoints (infected pancreatic necrosis, bacteraemia, pneumonia,
urosepsis or infected ascites). Pathogens cultured from the 87
patients with an infectious complication showed no significant
differences between the groups. However, mortality in the
probiotics group was significantly higher than in the placebo
group (16% vs. 6%, respectively).
This result was unexpected in light of the results of the animal
studies referred to in the trial protocol (the English protocol [2]
cites Mangiante et al. 2001 [3], the Dutch protocol [4] refers to
Mangiante et al. 2001 [5] and Lutgendorff et al. 2006 [6]). Lack of
correspondence between animal data and results from clinical
trials is not uncommon. It has been suggested that in order to
increase the potential value of animal studies as a preparation for
clinical applications not only the methodological quality of the
individual animal studies needs to be improved [7,8,9], but
systematic reviews (SRs) should become the standard method for
analysing preclinical studies in relation to one another. By means
of such reviews (particularly if they include a meta-analysis),
information relevant for judging the safety and efficacy of drugs/
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treatments may be obtained that is not directly visible from the
individual animal studies [10,11].
Therefore, in this paper, we used the methods of systematic
review and meta-analysis to take a closer look at the relation
between the animal studies on probiotics and pancreatitis and the
PROPATRIA-trial. We focussed on two questions: (1) Could a
more thorough analysis of the animal studies carried out before the
start of the trial have revealed indications for the harmful effects of
probiotics found in the PROPATRIA-trial? and (2) What would
the result of such an analysis be regarding the overall efficacy of
probiotics on the main outcome measures of the PROPATRIA-
trial (mortality, histopathology of the pancreas, bacterial translo-
cation to the pancreas or the mesenteric lymph nodes)? Moreover,
given that after the start and the completion of the PROPATRIA-
trial, more animal experiments on the subject were published, we
tried to answer the same questions taking all animal experiments
on probiotics and pancreatitis into account.
Materials and Methods
1. Search Strategy and Selection of the Papers
We searched PubMed and Embase for original articles
concerning the effects of probiotics on experimental acute pancreatitis until
August 5, 2011. The search strategy was composed of three
elements: pancreatitis, probiotics, and animals (for complete
search strategy see Table 1). It was developed in cooperation
with experts/information specialists from the Medical Library of
the Radboud University Nijmegen, the Netherlands. To detect all
animal studies in both PubMed and Embase, search filters were
used [12,13]. Furthermore, the reference lists of the selected
relevant papers were screened by hand for potentially relevant new
papers. No language restriction was used. If necessary, papers in
languages other than English were translated by scientists (native
speakers for that particular language) within the Radboud
University Nijmegen Medical Centre. The selection of studies
was performed on the basis of the title and abstract. In case of
doubt, the entire publication was purchased and evaluated. Two
investigators (C. Hooijmans and R. de Vries) independently
screened all the abstracts for the inclusion criteria. Differences
were resolved by a third investigator (M. Ritskes-Hoitinga). Studies
were included if they studied the effects of probiotics on mortality,
histopathology of the pancreas or bacterial translocation to the
pancreas or mesenteric lymph nodes(MLN), in experimental acute
pancreatitis. Papers were excluded if they fulfilled one of the
following criteria: (1) Not an original paper (e.g. review or letter
etc.); (2) Probiotic supplementation was combined with other
(nutritional) components; (3) Double publication; in case a paper
occurred more than one time in one of the databases, only the
original manuscript was included. The inclusion criteria and
methods of analysis were specified in advance and documented in
a protocol.
2. Study Characteristics and Data Extraction
From the studies included, the following data were extracted:
animal species, strain, age or body weight of animals at the
beginning of the study, gender, description of control group,
method of AP induction, type and dose of probiotics, timing of
probiotic supplementation relative to AP induction, duration of
probiotic supplementation, route of administration, timing of data
collection, number of animals in treatment and control group,
number of animals excluded for statistical analysis, reason for
excluding animals, outcome measures (Table 2). Bibliographic
details such as author, journal, year of publication and original
language were also registered. Four outcome measures were
included in the meta-analysis: mortality, bacterial translocation to
the pancreas and MLN and histopathology of the pancreas. In
order to assess the pathology of the pancreas overall pathology
scores were recorded. In case only specific pathology scores were
presented (e.g. inflammation and parenchymal necrosis) an overall
score with its variance was calculated by averaging all separate
means by uniform weighing [14]. For all studies, number of events
or mean, standard deviation (SD) or standard error (SE) and total
number of animals per group were recorded. If data were only
presented graphically, attempts were made to obtain data from the
authors; if these data were not made available, data were
measured using an universal on-screen digitizer where possible
(Universal Desktop Ruler). With this software it is possible to
measure distances, areas and perimeters of figures on a computer
screen.
3. Assessment of Risk of Bias in Included Studies
We assessed the risk of bias of the included studies using the
criteria/items described in Table S1. We based these criteria on
the possible presence of selection bias (items 1, 2 and 3),
performance bias (items 4 and 7), detection bias (items 5, 6 and
8) and attrition bias (items 9 and 10) [15]. The criteria were
independently assessed by two reviewers (C. Hooijmans and R. de
Vries) by using collectively predefined judging criteria. The score
‘‘yes’’ indicates low risk of bias, the score ‘‘no’’ indicates high risk
of bias, ‘‘?’’ indicates unknown risk of bias.
4. Data Synthesis and Statistical Analysis
For the outcome measure ’’histopathology of the pancreas’’, the
standardized mean difference (SMD) was calculated (the mean of
the experimental group minus the mean of the control group
divided by the pooled SD of the two groups), for all other outcome
measures (i.e. bacterial translocation and mortality) the Odds
Ratio was determined. If continuous data were presented, data
were discussed and presented in the tables but not included in
meta-analysis. Where outcomes were measured repeatedly on
different time points, we used the time point at which the
measured efficacy was greatest [16]. In one study, histopatholog-
ical data was presented as median and percentiles, these data were
converted to mean and SD [17]. In case histopathological data
was not presented in an overall score, we calculated an overall
score by uniformly weighing the separate means and SE’s of
fibrosis, acinar cell loss etc.
Despite anticipated heterogeneity, the individual effect sizes
(either OR or SMD) were pooled whenever possible (starting from
two studies or more) to obtain an overall effect size and 95%
confidence interval. We used the random effects model [18],
which accounts for anticipated heterogeneity. Subgroup analyses
were planned for the following study characteristics: year of
publication (before or after the publication of the trial protocol of
Besselink et al in 2004 [2]) and study design (comparable design to
Besselink et al [2]). In order to explore possible causes for
heterogeneity, subgroup analyses were planned for the following
study characteristics: timing of probiotic supplementation (before
or after induction of AP), type of probiotic supplement (multi
strains vs single strain).
The subgroup analyses were only performed if the overall meta-
analysis contained a minimum of 4 studies. Since there are
relatively few studies in each subgroup, the estimates of the
variances within a subgroup are not likely to be reliable. In
addition, we expected the variance to be comparable within the 2
subgroups; therefore, we assumed a common among study
variance across subgroups. Because of low power, no statistical
tests were used to confirm differences between subgroups.
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To detect publication bias, funnelplots were created and
explored. Meta-analysis was performed using Comprehensive
Meta Analysis (CMA version2.0). Forest plots were used to display
the mean overall effect sizes, together with effect sizes for
subgroups.
In order to assess the robustness of our findings and in an
attempt to further explain observed study heterogeneity, we
performed a sensitivity analysis and we investigated the effect of
possible interactions by species and quality. Because of the small
number of experiments in these subgroups interactions, the results
of this sensitivity analysis and interactions should be interpreted
with caution.
Results
1. Description of the Included Studies
The search strategy described in Table 1 retrieved 38 papers in
PubMed and 71 papers in Embase. Initially, 21 papers seemed to
meet our selection criteria. After studying the full-text articles, 13
original studies remained [5,14,16,17,19,20,21,22,23,24,25,26,27]
(Fig. 1).
The characteristics of these studies are shown in Table 2. Four
of these studies needed to be translated since they were published
in Chinese [21,22,24,27]. The study characteristics varied
considerably between the included papers. Twelve studies were
performed with rats and one used dogs. Nine studies used only
males, one study used females, and three papers did not mention
the gender of the animals. Seven different techniques were used to
induce AP. Also the timing of probiotic supplementation varied
greatly between the studies. Six papers mentioned supplementing
probiotics after AP induction, 4 studies before AP induction and 3
studies started probiotics supplementation before AP induction
and continued supplementation until a few days after AP
induction. In four experiments the effects of probiotic supplemen-
tation on mortality in experimental acute pancreatitis were
studied. Seven studies presented an overall histopathological score
of the pancreas, of which six could be included in the meta-
analysis. Eleven experiments (extracted from 8 papers) studied the
effects of probiotics on bacterial translocation (BT) to the MLN.
Eight of the experiments could be included in the meta-analysis.
Eight studies studied the effect of probiotics on BT to the pancreas,
five of these studies could be included in the meta-analysis.
2. Risk of Bias and Quality of Reporting
Figure 2 shows the overall results of the risk of bias assessment of
the 13 studies included in this SR. 77% of the studies stated that
the allocation of the experimental units to the treatment groups
was randomized. However, only two of these studies mentioned
the method of randomization used and only one provided
sufficient details so that the adequacy of the method could be
judged. None of the papers described whether or not the allocation
to the different groups during the randomization process was
concealed. 54% of the studies reported that they blinded the
outcome assessment. Table S1 shows that only four out of the 13
studies scored 5 out of the 10 items as low risk of bias. All of these
papers were written in the English language, and none of them
were published before the study protocol of Besselink et al. In
addition, Figure 2 clearly shows that many items were scored as
‘‘unclear risk of bias’’, which indicates poor reporting of animal
studies in scientific publications. This is also highlighted in Table 2,
which shows, for example, that in 31% of the studies the exact
timing of probiotic supplementation relative to AP induction was
not clear and in 23% of the studies the gender of the included
animals was not mentioned.
3. Publication Bias
The presence of publication bias was assessed for the outcome
measures BT MLN and BT liver since those outcomes contained
at least ten or more studies. However, the variation in SE was too
small to interpret the funnel plots reliably (data not shown).
4. Effects of Probiotic Supplementation
4.1. Mortality. Four experiments studied the effect of
probiotic supplementation on mortality in experimental AP.
Three of these studies could be included in the meta-analysis (as
in one study the number of animals per group was unclear). None
of these three studies showed a significantly reduced risk on
Table 1. Search strategy.
PubMed
Component 1: pancreatitis "pancreatitis"[MeSH Terms] OR "pancreatitis"[tiab] OR "ANP"[tiab] OR "Pancreatitides"[tiab] OR ("pancreas"[tiab] AND
"inflammation"[tiab])
Component 2: probiotics "probiotics"[MeSH Terms] OR "probiotics"[tiab] OR "probiotic"[tiab] OR "bifidobacterium"[MeSH Terms] OR
"bifidobacterium"[tiab] OR "bifidobacteria"[tiab] OR "lactobacillus"[MeSH Terms] OR "lactobacillus"[tiab] OR
"saccharomyces"[MeSH Terms] OR "saccharomyces"[tiab] OR "sporobacterin"[Substance Name] OR
"sporobacterin"[tiab] OR "bacillus subtilis"[MeSH Terms] OR ("bacillus"[tiab] AND "subtilis"[tiab]) OR "lactococcus
lactis"[MeSH Terms] OR ("lactococcus"[tiab] AND "lactis"[tiab]) OR "synbiotic"[tiab] OR "synbiotics"[tiab] OR "lactic acid
bacteria"[tiab]
Component 3: animal Search filter for animal studies [13]
Embase
Component 1: pancreatitis (exp pancreatitis/OR pancreatitis.ti,ab. OR pancreatitides.ti,ab. OR ANP.ti,ab. OR (pancreas.ti,ab. AND
inflammation.ti,ab.) OR (pancreatic.ti,ab. AND inflammation.ti,ab.))
Component 2: probiotics (exp probiotic agent/OR probiotics.ti,ab. OR probiotic.ti,ab. OR probiotica.ti,ab. OR exp synbiotic agent/OR
synbiotic.ti,ab. OR synbiotics.ti,ab. OR exp bifidobacterium/OR bifidobacterium.ti,ab. OR bifidobacteria.ti,ab. OR exp
lactobacillus/OR lactobacillus.ti,ab. OR lactobacilli.ti,ab. OR lactobacterium.ti,ab. OR lactobacteria.ti,ab. OR exp
lactococcus/OR lactococcus.ti,ab. OR lactococci.ti,ab. OR exp bacillus/OR bacillus.ti,ab. OR bacilli.ti,ab. OR exp
saccharomyces/OR saccharomyces.ti,ab. OR sporobacterin.ti,ab. OR exp lactic acid bacterium/OR lactic acid
bacteria.ti,ab. OR lactic acid bacterium.ti,ab. OR Nissle 1917.ti,ab.)
Component 3: animal Search filter for animal studies [12]
doi:10.1371/journal.pone.0048811.t001
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mortality due to probiotic supplementation in experimental AP.
Meta- analysis also showed no effect (Fig. 3; OR 0.54 [0.24, 1.22];
n = 3). Heterogeneity was low (Q=0.62, p = 0.73; I2 = 0.0%), and
all included studies used rats.
The study of Yang et al 2006 [27], which could not be included
in meta-analysis, also showed no significant reduction in mortality
due to probiotic supplementation in experimental AP.
4.2. Histopathology of the pancreas. Six out of 7 papers
investigating the effect of probiotic supplementation in experi-
mental AP on histopathological abnormalities in the pancreas
could be included in meta-analysis. Four of these papers showed a
significant reduction of the total histopathological score due to
probiotic supplementation compared to controls. Overall analysis
also showed that probiotic supplementation reduced/improved
the overall histopathological score of the pancreas (Fig. 4; SMD
21.35 [22.43, 20.26]; n = 6; p = 0.015). Heterogeneity was high
(Q=34.53, p,0.01; I2 = 85%), although all studies were per-
formed in one species (rats).
Figure 1. Flow diagram of the systematic review and meta-analysis literature search results.
doi:10.1371/journal.pone.0048811.g001
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Before the publication of the study protocol, solely the study of
Akyol [20] had been published (Fig. 4b). This specific paper
showed lower histopathological scores in the probiotic group as
compared to controls (p = 0.037). The results of the study of Akyol
were in accordance with the results of the overall analysis [20].
Subgroup analysis also revealed that in studies supplementing
probiotics after AP induction a significant decrease in the
histopathological score was present, whereas in studies supple-
menting probiotics before AP no significant decrease was observed
(Fig. 4; after; SMD 21.89 [23.02, 20.58]; n = 49; p,0.01before;
SMD 20.31 [22.11, 1.50]; n = 2; p= 0.74).
Subgroup analyses on the study characteristic ‘‘type of probiotic
supplement’’ showed that single strain supplementation reduced
the overall histopathological score of the pancreas, whereas
multistrain supplementation did not (Fig. 4b). Subgroup analysis
did not reduce heterogeneity.
4.3. Bacterial translocation to the pancreas. The effect of
probiotic supplementation on bacterial translocation (BT) to the
pancreas was studied in eight papers. Five of these studies
presented their data as a binary outcome (presence or absence of
bacterial translocation) and three others presented their data as a
continuous variable (amount of colony forming units/g). Only
binary outcomes were included in the meta-analysis.
The five experiments that could be included in the meta-
analysis showed that the odds of BT to the pancreas is less likely to
occur in the probiotic group as compared to the control treated
groups (OR 0.24 [0.06, 0.99]; n = 5; p = 0.049). Heterogeneity was
moderate (Q= 8.57, p = 0.073; I2 = 53%). Three studies using
continuous variables for BT to the pancreas also showed
significant reductions in the number of bacteria translocated to
the pancreas in the probiotic group (Fig. 5c).
Before the publication of the trial protocol by Besselink et al
2004 [2], four studies concerning probiotic supplementation in
experimental AP were published. Meta-analysis, which could
include 3 of these studies, revealed that at that time the overall
effect on BT to the pancreas was already significant (OR 0.12
Figure 2. Risk of bias, averaged per item. yes = low risk of bias, no= high risk of bias, ? = unclear risk of bias, n.a. = not applicable.
doi:10.1371/journal.pone.0048811.g002
Figure 3. Effects of probiotic supplementation on mortality in experimental acute pancreatitis. Forest plot of the data of three included
studies. The forest plot displays the OR, 95% confidence interval and relative weight of the individual studies. The diamond indicates the global
estimate and its 95% confidence interval.
doi:10.1371/journal.pone.0048811.g003
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[0.02, 0.60]; n = 3; p = 0.01). Two of these studies were really
indicative for the planned trial, because those studies supplement-
ed probiotics after induction of AP. Subgroup analysis of these 2
studies showed that there was at that time already a significantly
reduced risk of BT to the pancreas in probiotic treated animals
with AP (OR 0.08 [0.01, 0.95]; n = 2; p = 0.046).
Comparison of the effects of probiotic supplementation before
or after inducing experimental AP on the risk of BT to the
pancreas revealed that supplementation of probiotics before
inducing AP has no significant effect (OR 0.63 [0.10, 3.76];
n = 2; p= 0.61) in contrast to supplementation of probiotics after
inducing AP (OR 0.09 [0.03, 0.57]; n = 3; p= 0.01).
Subgroup analysis on the timing of probiotic supplementation
did not reduce heterogeneity substantially, and remained moder-
ate. Subgroup analyses on the study characteristic ‘‘type of
probiotic supplement’’ showed also here that single strain
supplementation might reduce the risk of BT to the pancreas in
probiotic treated animals with AP, whereas with multistrain
supplementation no such an effect could be observed (Fig. 5b).
Heterogeneity levels clearly decreased in the subgroup single strain
(Q=0.33, p = 0.56; I2 = 0.0%).
4.4. Bacterial translocation to the mesenteric lymph
nodes (MLN). The effect of probiotic supplementation on
bacterial translocation (BT) to the MLN was studied in nine
papers. Five of these studies (including 8 experiments) presented
their data as a binary outcome and three others presented their
data as a continuous variable (amount of colony forming units/g).
Only binary outcomes were included in the meta-analysis.
Overall analysis revealed that probiotics reduced the risk of BT
to the MLN (Fig. 6a; OR 0.25 [0.11, 0.58]; n = 8; p,0.01).
Heterogeneity was low (Q=4.23, p = 0.753; I2 = 0.0%).
Before the publication of the study protocol of Besselink et al.
[2] three studies investigated this outcome measure as well (of
which 2 could be included in meta-analysis). However, only one
study had a comparable design (i.e. probiotic supplementation
after AP induction). This study showed no significant reduction of
the risk of BT to the MLN due to probiotic supplementation (OR
0.09 [0.01, 2.16]; p = 0.14).
Subgroup analysis (Fig. 6b) on the effects of the timing of
probiotic supplementation relative to AP induction could only be
performed with 4 studies, because the other 4 experiments did not
describe the timing of supplementation. This analysis showed that
both probiotic supplementation before and after AP induction
could be beneficial (Fig. 6b ). The results of the studies presenting
continuous data (except for van Minnen et al [26] and Tarasenko
Figure 4. Effects of probiotic supplementation on histopathological damage to the pancreas in experimental acute pancreatitis. (a)
Forest plot and (b) subgroup analysis of the data of six included studies. The forest plot displays the SMD, 95% confidence interval and relative
weight of the individual studies. The diamond indicates the global estimate and its 95% confidence interval.
doi:10.1371/journal.pone.0048811.g004
Probiotics in Experimental Acute Pancreatitis
PLOS ONE | www.plosone.org 7 November 2012 | Volume 7 | Issue 11 | e48811
et al [16], after 2 h) are in accordance with the results of the meta-
analysis (Fig. 6c).
Subgroup analyses on the study characteristic ‘‘type of probiotic
supplement’’ showed that both single strain supplementation and
multistrain supplementation seem to reduce BT to the MLN
(Fig. 6b). The effect appears to be larger in the single strain group
as compared to the multistrain group (single; OR 0.15 [0.05,
0.53]; n = 2; p,0.01, multi: 0.371 [0.12, 1.11]; n = 6; p= 0.08).
5. Sensitivity Analysis and Interactions
To assess the robustness of our findings and in an attempt to
further explain the observed study heterogeneity, we performed a
sensitivity analysis and we investigated the effect of possible
interactions by species and quality.
In the analysis of outcome measures BT to the pancreas and
MLN also a dog study was included. Analyzing the outcome
measures without this dog study resulted in different results for the
outcome measure BT to pancreas. The odds of BT to the pancreas
Figure 5. Effects of probiotic supplementation on bacterial translocation to the pancreas in experimental acute pancreatitis. (a)
Forest plot and (b) subgroup analysis of the data of five included studies. The forest plot displays the OR, 95% confidence interval and relative weight
of the individual studies. The diamond indicates the global estimate and its 95% confidence interval. (c) effectsizes and 95% confidence interval of
three studies presenting continuous data which were not included in meta-analysis in order to reduce heterogeneity.
doi:10.1371/journal.pone.0048811.g005
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was no longer less likely to occur in the probiotic group as
compared to the control groups (OR 0.29 [0.05, 1.57]; n = 4;
p = 0.15). Heterogeneity remained moderate (Q= 7.67, p = 0.05;
I2 = 60%).
Sensitivity analysis revealed that excluding the studies with an
overall quality score lower than 60% (Table 2) solely altered the
results of BT to the pancreas. The excluded study for this outcome
measure was again the dog study and therefore the sensitivity
analysis showed the same results as mentioned above.
Discussion
The results of this SR and meta analysis show that a more
thorough analysis of all relevant animal studies carried out before
Figure 6. Effects of probiotic supplementation on bacterial translocation to the mesenteric lymph nodes (MLN) in experimental
acute pancreatitis. (a) Forest plot and (b) subgroup analysis of the data of eight included experiments. The forest plot displays the OR, 95%
confidence interval and relative weight of the individual studies. The diamond indicates the global estimate and its 95% confidence interval. (c)
effectsizes and 95% confidence interval of three studies presenting continuous data which were not included in meta-analysis in order to reduce
heterogeneity.
doi:10.1371/journal.pone.0048811.g006
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the start of the PROPATRIA trial [1], would not have revealed
indications for harmful effects of probiotics. A combination of the
results of all four animal studies published before the trial did not
show an adverse effect on the main outcome measure (i.e.
mortality). Moreover, it did show a positive effect on other
outcome measures, namely improved histopathology of the
pancreas and reduced bacterial translocation to the pancreas
and to the MLNs. These overall conclusions do not change when
all animal studies on probiotics and pancreatitis published so far –
including the ones performed after the PROPATRIA trial - are
taken into account.
The PROPATRIA-trial in humans showed higher mortality in
the group treated with probiotics [1]. This result was unexpected
in light of the results of the animal studies referred to in the trial
protocol by Besselink et al. [2,4]. The protocol referred (indirectly)
to one animal study published before the start of the trial (namely
Mangiante et al. 2001 [5]), which showed some evidence for
reduced bacterial translocation to the pancreas and MLN, but did
not study the effect of probiotics during AP on mortality. We were
able to identify three other animal studies that had already been
published at the time (Deng et al. 2000 [22], Tarasenko et al.
2000 [16], Akyol et al. 2003 [20]). Of these three, only one study
(Akyol et al. 2003 [20]) reported data on mortality and this study
showed a non-significant reduction of mortality. Because mortality
was not intended to be a primary outcome measure in most of the
animal studies, the experiments may have been underpowered to
be able to detect a possible significant difference in mortality
between probiotic treated and control groups. Even though
Tarasenko et al. 2000 [16] and Mangiante et al. 2001 [5] did
not provide data on mortality, the former emphasized that B.
subtilis did not aggravate the course of experimental AP and the
latter stressed that, as a proof of the safety of the probiotic
prophylaxis, they never found L. plantarum in blood samples, also
not in samples from animals with BT. In other words, although
only very few animal experiments had been carried out and data
on mortality available were not fully reliable, there were at the
start of the PROPATRIA trial no indications from animal
experiments that probiotics might have a harmful effect. None
of these four studies, however, supplemented the probiotic
Ecologic 641, which was used in the trial.
Also inclusion of more recent animal studies does not provide
evidence for an increase in mortality due to probiotic supplemen-
tation. Nevertheless, we found one study that reported a tendency
towards adverse effects of probiotics: Horst et al. (2009) [23]
showed a higher histopathological score and an increase in
bacterial translocation to the pancreas after probiotic supplemen-
tation. Both effects were not statistically significant, however, and
did not alter the direction of the overall effect in the meta-analysis.
The most striking differences between the study of Horst et al. [23]
and the other studies are the duration of probiotic supplementa-
tion before AP induction (14 days in the Horst study; on average
4–5 days in the other studies) and timing of the outcome
assessment (12 hours after AP induction in Horst et al.; on
average 4 days after AP induction in all other studies). However,
although the results of the study of Horst et al. were closer to the
clinical truth, the above mentioned differences do not offer an
obvious explanation for this.
With regard to the efficacy of probiotics in AP, the combined
analysis of the four animal studies executed before the start of the
trial showed that probiotic supplementation did not affect
mortality, but led to an improved histopathological score for the
pancreas and reduced bacterial translocation to pancreas and
MLNs. These results remained largely the same when only the
studies were taken into account that used probiotic supplemen-
tation after induction of AP (so with a design comparable to the
PROPATRIA-trial). In addition, including also the more recent
studies does not alter these results. In summary, the animal studies
on probiotics and AP showed improvement in two important
clinically relevant outcome measures, namely pancreatic histopa-
thology and reduced bacterial translocation, and had no effect on
the main outcome measure, mortality.
Most of the studies were originally not designed to measure an
effect of probiotics on mortality and might for this reason be
underpowered. Moreover, the timing of the determination of
mortality should be taken into account. In humans, acute
pancreatitis typically follows a biphasic course: the early phase is
associated with systemic inflammatory response syndrome (SIRS),
(multiple) organ damage and early mortality (,1 week), the late
phase is characterized by infectious complications following
bacterial translocation of intestinal bacteria and late mortality
(.3 weeks). Given that only the late mortality is mediated by
infection/bacterial translocation, an effect of probiotics on early
mortality is not to be expected. If acute pancreatitis in laboratory
animals follows a similar course, and there are indications that this
is the case [26], then the focus should be on an effect on late
mortality. A closer look at 3 out of 4 experiments reporting also a
late mortality reveals that only the study of Van Minnen et al. [26]
detected a significant reduction, whereas the others did not find
any differences in late mortality. In other words, also on closer
inspection, no overall positive or negative effects of probiotic
supplementation on late mortality were found.
In light of the results presented above – no indications for
harmful effects and quite strong evidence for efficacy – and given
the regulatory requirements for food supplements (to which
probiotics belong), it was defensible and understandable that the
PROPATRIA-trial was started. However, there are some meth-
odological issues which may hamper the interpretation of the
experimental animal data and subsequently the translation to the
clinical setting.
First of all, there were substantial differences in the design of the
trial and the design of the animal experiments: a) all animal studies
conducted before the start of the trial used other probiotic
products than the one used in the trial, and in most cases single
strain probiotics were tested in animals whereas PROPATRIA
used multistrain probiotics Ecologic 641. After the start of the trial,
some animal studies using Ecologic 641 have been published.
However, none of these studies used both administration of
probiotics after induction of AP and outcome measures compa-
rable to the ones used in the PROPATRIA-trial. b) in the trial
probiotics were administered in the jejunum whereas in most
animal studies it was administered in the stomach, c) in 50% of the
animal studies probiotic supplementation started before inducing
AP, whereas in the PROPATRIA trial probiotica was supple-
mented to patients already suffering from severe AP. The exact
physiological and translational significance of these differences is
currently unclear and needs further study. Nevertheless, it is
remarkable that an animal study with a study design similar to the
human trial has not yet been conducted (i.e., an animal
experiment studying the effect of Ecologic 641 supplemented in
the jejunum after induction of AP on mortality and translocation/
infection). In case such an experiment had been performed and
the result had demonstrated an increased risk of mortality, we
believe it would not have been responsible to start a clinical trial
before conducting more similar experiments with a comparable
design. In case this hypothetical experiment had shown no change
or a diminished risk on mortality, a decision to go ahead would
have been justified, also because a clinical trial with positive results
of the use of probiotics in humans had been published already.
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Second, the heterogeneity among the various animal studies is
quite considerable. We tried to explain this heterogeneity through
subgroup analyses (supplementation of probiotics before or after
induction of AP, use of probiotics containing a single or multiple
strains of bacteria), but in most cases these subgroup analyses did
not substantially reduce the heterogeneity. Despite these limita-
tions, the combined analysis still produced extra and useful
information that could not directly be derived from the individual
studies. Subgroup analyses showed for example that single strain
probiotic supplementation might be more effective in reducing the
overall histopathological score of the pancreas and the risk of
bacterial translocation, as compared to multistrain supplementa-
tion. In future animal studies and clinical trials it seems worthwhile
to investigate the possible difference in efficacy between mulit-
strain and single strain probiotic mixtures.
Third, at the time that the PROPATRIA trial started only a few
experimental animal studies had been published (n= 4) with
relatively few animals per study. As a consequence, the power of
the meta analysis, and thereby the reliability of the conclusions (the
overall effect sizes), is relatively low. This limitation applies even
more strongly to the subgroup analyses. For that reason,
particularly the conclusions of the subgroup analyses should be
treated as indications that elicit further investigation, rather than
as hard conclusions.
Fourth, poor reporting of crucial pieces of information in the
original manuscripts is of serious concern, and is also addressed by
others [7,8,9,28,29]. This seriously hampers drawing reliable
conclusions from animal studies. The risk of bias assessment and
the table describing the characteristics of the included studies have
clearly shown that crucial pieces of information (such as the timing
of probiotic supplementation relative to the induction of AP, the
number of animals per group included in the statistical analyses
and the reasons for excluding animals) are often not well reported.
Furthermore, only half of the studies reported that they blinded
the outcome assessment and only one study provided sufficient
details to judge the adequacy of the method of randomization. If
the other studies did not actually blind the outcome assessment
and if the methods of randomization used in the other studies were
inadequate, there is a substantial risk that the effects of probiotics
have been overestimated (see also [11]). If the actual effects of
probiotics are indeed smaller than reported, it remains to be seen
whether these effects are still statistically significant.
All in all, this SR has demonstrated that combining the results of
all relevant animal studies published before and after the trial does
not show an adverse effect of probiotic supplementation on the
main outcome measure mortality, and shows a positive effect on
the other outcome measures (reduced histopathology of the
pancreas and BT to the pancreas and MLNs). In addition,
subgroup analyses revealed that single strain probiotic supple-
mentation might be more effective in reducing the overall
histopathological score of the pancreas and the risk of bacterial
translocation, as compared to multistrain supplementation.
Therefore, we conclude that a more thorough analysis of all
relevant animal studies (published both before and after the study
protocol of the PROPATRIA trial) could not have predicted the
harmful effects of probiotics supplementation as found in the
PROPATRIA-trial.
However, it has also become clear that no animal study followed
the experimental design of the human PROPATRIA trial as
closely as possible, i.e., studying the effect on mortality and
infection of supplementation in the jejunum of Ecologic 641 after
induction of AP, which compromises a fair comparison between
the results of the animal studies and the PROPATRIA trial.
Moreover, a substantial portion of the animal studies had
methodological shortcomings: insufficient power, potentially inad-
equate methods of randomisation and absence of blinding. In
other words, the animal experiments were not executed and
evaluated in such a way that the chances of a successful translation
to the clinic were maximal. Yet, it is vital, both to justify the
suffering of laboratory animals and to prevent harm in human
patients, that the animal experiments conducted prior to clinical
application are carried out in such a way that they yield the most
and most reliable information. To prevent misunderstanding,
there might be other factors that may explain (part of) the
extrapolation problems. For example, there might be immuno-
logical differences between humans and other animal species as
well as differences in the type of pancreatitis. These differences
may further interfere with extrapolation of outcome data from
animals to humans. It is too early, however, to conclude that
animal experiments either can or cannot reliably inform regarding
the potential outcome of human studies. Before drawing such a
conclusion, it is important to first optimize the execution of
preclinical animal experiments (through a design as close as
possible to the intended clinical application, clear and clinically
relevant primary outcome measures, proper power calculation,
etc.). Accordingly, we strongly recommend a broad and explicit
debate about the standards of animal experiments preceding
clinical application.
Supporting Information
Table S1 Risk of bias of individual studies. yes = low risk
of bias, no= high risk of bias, ? = unclear risk of bias, n.a. = not
applicable. * = assesment of the oucome measure histopathology
was blinded, other relevant outcome measures were not blinded. ‘‘
Risk of bias in the analysis because animals were replaced.# solely
animals with severe AP are included in the analysis (risk of
underestimating the effect of probiotics).
(XLS)
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